PharmaEssentia Corporation (TPE:6446)

PharmaEssentia Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	20,752	15,635	9,735	5,106	2,882	656.51
Revenue Growth	64.24%	60.61%	90.67%	77.15%	339.00%	17.81%
Gross Profit Gross Profit Growth	18,863	13,950	8,558	4,495	2,070	277.65
Operating Income Operating Income Growth	7,967	4,928	1,736	-1,913	-2,028	-2,822
Net Income Net Income Growth	7,629	5,045	2,966	-623.84	-1,375	-2,811
Earnings Per Share EPS Growth	18.50	12.25	7.21	-1.57	-3.93	-8.78
EPS Growth	87.99%	69.88%	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue from Sale of Medicine Products Revenue from Sale of Medicine Products Growth	17,376	15,551	9,674	4,941	2,879	633.15
Revenue from Royalty Income Revenue from Royalty Income Growth	93.92	52.91	-	-	-	-
Revenue Arising from Rendering of Services Revenue Arising from Rendering of Services Growth	28.52	31.26	28.87	11.39	2.64	23.36
Other Sales Other Sales Growth	-	-	31.96	153.58	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	24,471	22,693	21,051	19,666	10,304	3,454
Total Debt Total Debt Growth	1,022	856.03	965.43	1,200	1,569	536.24
Net Cash (Debt) Net Cash Growth	23,449	21,837	20,086	18,466	8,735	2,917
Net Cash Growth	18.20%	8.72%	8.77%	111.40%	199.41%	13.71%
Net Cash Per Share Net Cash Per Share Growth	56.86	53.04	48.85	46.52	24.97	9.11

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	8,275	5,278	2,525	-709.51	-1,505	-2,462
Capital Expenditures CapEx Growth	-2,342	-1,911	-862	-1,286	-312.03	-70.33
Free Cash Flow Free Cash Flow Growth	5,933	3,366	1,663	-1,996	-1,818	-2,532
Free Cash Flow Growth	207.16%	102.47%	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	90.90%	89.23%	87.91%	88.04%	71.82%	42.29%
Operating Margin	38.39%	31.52%	17.83%	-37.48%	-70.37%	-429.91%
Pretax Margin	43.18%	31.87%	30.76%	-19.33%	-63.91%	-428.17%
Profit Margin	36.76%	32.27%	30.46%	-12.22%	-47.70%	-428.17%
FCF Margin	28.59%	21.53%	17.08%	-39.09%	-63.06%	-385.74%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Aug 19, 2026	Dec 31, 2025	Dec 31, 2024
Dividend Per Share Dividend Per Share Growth	0.992	0.992	0.894
Dividend Per Share Growth	0%	10.97%	-
Dividend Yield	0.07%	0.23%	0.18%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 19, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	75.68	34.45	69.04	-	-	-
Forward PE	46.38	25.16	41.36	31.89	69.03	-
P/FCF Ratio	97.80	51.64	123.13	-	-	-
PS Ratio	27.96	11.12	21.03	22.44	49.91	118.91

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error